Get started
CARMAT SAS EURONEXT LONGCarmat SAS is a France-based Company engaged in the development and production of heart prosthesis. enter price:25.8; stop-loss 23.30; target price 33.60. Carmat's RSI looks strong and shows upwards momentum, therefore a drastic trend reversal or corrective pullback are unlikely to occur in the near future. DMI the indicator in these situation can't be easily interpreted but we can identify a little bullish trend that is ready to growth. MACD suggest that the graph is in a good bull trend. The news told that Carmat has lunch its product in the U.S in 23 september. this fact can uphold our analysis. NO FINANCIAL ADVISE
EURONEXT:ALCARLong
by vf_investment
ALFEN Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
EURONEXT:ALFENShort
by hadimozayan
LVMH (MC.PA)LVMH is a vastly diversified company with 75+ brands from fashion, jewelry, leather, cosmetics, perfumes, stores, alcohol, media and financial services. LVMH has a few of the most desirable luxury brands in the world in its portfolio. Inflation isn't a problem at all, but more a possible catalyst for the company: high-end luxury items are investments and collectables. LVMH had a good start in 2021: all business segments contributed to organic revenue growth. Please take a look here: r.lvmh-static.com LVMH overvaluation is not the specfic problem for LVMH, but for the entire stock market. The inflation is not the problem: luxury brands can increase the price. You should buy companies which can increase the price easily when the inflation is coming. LVMH is overvalued right now (5% -15%). It's not the right time to invest in this great company. Entry point could be around 570€. Own it, don’t trade it.
EURONEXT:MCShort
by mgiuliani
1
Trendchannel TKWYTKWY is in a downtrend at the moment. Set an alert at €82. If it breaks out of the channel it will probably move up. Large shareholders like Cat Rock Capital have been complaining about the shareprice of TKWY. They think shares of TKWY have a big discount compaired to their rivals. Also: BoA and Goldman both have a price target of €130-135 on TKWY. Will TKWY shake of the worries among shareholders about the takeover of GrubHub? Note: no financial advise! Just my opinion.
EURONEXT:TKWY
by Alexxbr_777
ATOS ATO long entry for swing tradeAssuming a correction of the last movement to the 38,2% fibo level around 41,2 Level confirmed by the c target of the abc ongoing correction stop easy under the last lows around 38,5 targets: either we are in a impulse wave --> target at least 161,8% fibo at 49 (orange scenario) or we are in ABC correction (red scenario) --> target when AB=BC, around 47 on the middle term we may be in a 4th wave of a bearish movement, therefore this trade is only for short term A lower low could come on the long term to complete the pattern see also .tradingview.com/chart/ATO/iLDRPY31-ATOS-looking-for-entry-point/
EURONEXT:ATOLong
by FabienGo
ALNOV Novacyt Graham Mullis, Group CEO of Novacyt, commented: “Novacyt is continuing to address COVID-19 testing for both current and future demand. We continue to ensure that innovation is at the centre of our strategy and that our growing portfolio of COVID-19 tests are available to customers in both private and public health settings to expand existing, and support new, partnerships. Throughout the pandemic, NHS testing demand has remained a key priority for the Company and the contract award under the PHE National Microbiology Framework is a testament to our continued commitment. “We believe our long-term strategy also supports the growth of Novacyt post-COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the COVID-19 testing opportunity but also ensure we are well placed, with both technologies and partners, for sustainable growth beyond COVID-19. We therefore believe Novacyt is well positioned to continue to build on its business transformation.” This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. About Novacyt Group The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
EURONEXT:ALNOVLong
by wallstreetstocks
LVMH (MC.pa) bearish scenario:The technical figure Rising Wedge can be found in French company LVMH Moët Hennessy Louis Vuitton (MC.pa) at daily chart. LVMH Moët Hennessy Louis Vuitton commonly known as LVMH, is a French holding multinational corporation and conglomerate specializing in luxury goods, headquartered in Paris, France. The Rising Wedge has broken through the support line on 19/08/2021, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 38 days towards 594.50 EUR. Your stop loss order according to experts should be placed at 716.60 EUR if you decide to enter this position. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:MCShort
by legacyFXofficial
Uuii UbisoftBuying points: -trend line from July,15 -strong support at 51.14€ -MACD: MA lines extremely under average -RSI: oversold Selling points: -all SMAs above the price -MACD shows negative momentum Fundamentals -selling pressure bc of bad earnings of the gaming industry (take-two) -seasonal summer impact -> people are more outside, fewer sales -guidance of next earnings: meh Conclusion Technically the stock has a great potential to bounce back to a certain level which I think is 59-60€. So, with a tight stop loss, we are looking for a 17% return. My strategy, in this case, is to sell the stock when it hits SMAs like 50 or 100 (main goal 100). You could argue that the share has the chance to get to the upper downtrend line but the fundamentals do not support this theory, not in the short-mid term. Short opportunities could arrive after we go under the trend and support line (full daily closed candle). This would become approximately 20% down to the next support line of 40€. As all ways, I try my best to calculate the best risk/reward ratio. If you like my analysis you can follow for more quality content.
EURONEXT:UBILong
by Chrlstlan